Go to main navigation Go to main content Go to footnote

REVERS: Study using postbiotics in AMD patients

If you are interested in taking part in a clinical trial, please send us your personal details here and we will assess whether you are eligible.


A study to assess the efficacy and safety of postbiotic supplementation in

1) Preventing AMD progression, its impact on the worsening of functional and anatomical assessment criteria in intermediate age-related macular degeneration (iAMD)

2) Slowing the progression rate of geographic atrophy (GA) in patients with late non-exudative AMD or macular dystrophies.

3) Improving the efficacy of antiangiogenic therapy in patients with choroidal neovascularisation and insufficient response to treatment.

Depending on the treatment group, subjects will be randomly assigned an approved nutritional supplement for the prevention of the progression of intermediate AMD (AREDS) or the same supplement enriched with postbiotics.

Patients older than 50 with intermediate AMD, geographic atrophy and choroidal neovascularisation in antiangiogenic treatment and with weak treatment response.

Postbiotics are compounds that are usually secreted by bacteria that live in our intestine. They may have direct and clinically relevant immunomodulatory effects. Studies may be found on the use of postbiotics in healthy individuals to improve overall health or to relieve symptoms in various diseases.

The duration of the study will be one year, with a possible two-year extension.

BMF carries out a program of clinical trials for researching new treatments for vision diseases. Contact us! You could be the patient we’re looking for.

I want to take part in the clinical trials

Research is the only solution for the future to fight against blindness

It is only with your help that we can fight against blindness